Samchundang Pharmaceutical is set to commercialize its Eylea biosimilar, SCD411, this year. With its overseas partners projecting sales of over 17 trillion KRW ($12.7 billion), the industry is watching closely to see if the product will successfully establish itself in the market. The company aims to leverage price competitiveness to secure market share. According to Samchundang Pharmaceutical o..

According to pharmaceutical market research firm IQVIA, Vegzelma achieved a 29% market share in Europe as of Q3 last year, surpassing all competing bevacizumab products, including the original drug. This milestone was reached just two years after its European launch in October 2022. In that quarter alone, Vegzelma's market share increased by 9 percentage points (9%P) compared to the previous qua..

Samsung Biologics announced on January 22 that it recorded KRW 4.55 trillion in revenue and KRW 1.32 trillion in operating profit on a consolidated basis last year. Revenue increased by 23%, and operating profit grew by 19% compared to the previous year. The company attributed the strong performance to increased sales from its fourth plant, full-capacity operation of its first to third plants, a..

The JP Morgan Healthcare Conference, now in its 43rd year, is the world's largest investment event for the pharmaceutical and biotech industries. This year, the conference brought together more than 550 companies and over 8,000 participants. Hugel participated as part of the Asia-Pacific (APAC) track and unveiled its future goals under the vision of "Becoming a Global Industry Leader." By 2028, ..